

HR 1353

PATIENT Act of 2015

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 13, 2015

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 20, 2015)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/1353>

Sponsor

Name: Rep. Bilirakis, Gus M. [R-FL-12]

Party: Republican • **State:** FL • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Connolly, Gerald E. [D-VA-11]	D · VA		Mar 13, 2015
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Mar 13, 2015
Rep. Israel, Steve [D-NY-3]	D · NY		Mar 13, 2015
Rep. Brooks, Susan W. [R-IN-5]	R · IN		Apr 28, 2015

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 20, 2015

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 or the PATIENT Act of 2015

This bill amends the Federal Food, Drug, and Cosmetic Act to extend to five years the three-year marketing exclusivity period provided to certain new drugs that include an active ingredient that was already approved by the Food and Drug Administration.

A drug is provided this extended exclusivity period if it is approved for a new indication or use, or the drug has been reformulated or redesigned to:

- promote greater patient adherence to an approved treatment regime,
- reduce the public health risks associated with the drug,
- reduce side effects or adverse events,
- provide benefits to the health-care system, or
- provide other comparable patient benefits.

Actions Timeline

- **Mar 20, 2015:** Referred to the Subcommittee on Health.
- **Mar 13, 2015:** Introduced in House
- **Mar 13, 2015:** Referred to the House Committee on Energy and Commerce.